Mineralys Therapeutics
NASDAQ: MLYSRadnor, US · Founded 2019 · Delaware corporation · 7 known investors
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
Founders & leadership
EW
Eric WarreninChief Commercial Officer
AG
Alex GoldChief Medical Officer
AL
Adam LevyNamed on SEC filing
AA
Alexander AsamNamed on SEC filing
Board
BT
Brian Taylor SlingsbyFounder & former CEO / Board DirectorFounder & Managing Director, MD, PhD, MPH at Catalys Pacific
OL
DD
JC
SA
Srinivas AkkarajuBoard director
TT
Investors · 7
Reported raises · per SEC filings
Form D private placements$118M disclosed across 1 round · 2022
▶$118MraisedJun 2022 · 23 investors · PharmaceuticalsRule 506(b)
▶$118MraisedJun 2022 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brian Taylor SlingsbyDirector
- Olivier LitzkaDirector
- Derek DiRoccoDirector
- Adam LevyExecutive Officer
- Jon CongletonExecutive Officer, Director
- Srinivas AkkarajuDirector
- Alexander AsamDirector
- Takeshi TakahashiDirector
- Offering amount
- $118M
- Amount sold
- $118M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Seeking Alpha20 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Exelixis18 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
TipRanks17 shared keywordsFinancial analysis and stock research platform.
Simply Wall St16 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies competing with Mineralys Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Mineralys Therapeutics do?
- Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
- Who are Mineralys Therapeutics's investors?
- Mineralys Therapeutics's investors include Andera Partners, Samsara BioCapital, SR One Capital Management, Ysios Capital, Boulder Ventures, Catalys Pacific, RA Capital.
- How much funding has Mineralys Therapeutics raised?
- Mineralys Therapeutics has disclosed $118M raised across 1 round.
- Where is Mineralys Therapeutics headquartered?
- Mineralys Therapeutics is headquartered in Radnor, US.